

Venous Thromboembolism: Practical Application of Clinical Practice Guidelines and Recent Research Results to Patient Cases

References

1. Anderson FA Jr, Wheeler HB, Goldberg RJ et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. *Arch Intern Med.* 1991; 151:933-8.
2. Geerts WH, Pineo GF, Heit JA et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest.* 2004; 126(3 suppl):338S-400S.
3. Goldhaber SZ, Tapson VF, DVT FREE Steering Committee. A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis. *Am J Cardiol.* 2004; 93:259-62.
4. Monreal M, Kakkar AK, Caprini JA et al. The outcome after treatment of venous thromboembolism is different in surgical and acutely ill medical patients. Findings from the RIETE registry. *J Thromb Haemost.* 2004; 2:1892-8.
5. Tapson VF, Decousus H, Bergmann JF et al. The International Medical Prevention Registry on Venous Thromboembolism (IMPROVE): Venous Thromboembolism Prophylaxis Practices in Acutely Ill Medical Patients. *Blood.* 2004; 104:11. Abstract #1762.
<http://meeting.bloodjournal.org/cgi/content/abstract/104/11/1762?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=tapson&searchid=1&FIRSTINDEX=0&volume=104&issue=11&resourcetype=HWCIT> (accessed 2007 Mar 20).
6. Aujesky D, Guignard E, Pannatier A et al. Pharmacological thromboembolic prophylaxis in a medical ward: room for improvement. *J Gen Intern Med.* 2002; 17:788-91.
7. Arnold DM, Kahn SR, Shrier I. Missed opportunities for prevention of venous thromboembolism: an evaluation of the use of thromboprophylaxis guidelines. *Chest.* 2001; 120:1964-71.
8. Dobesh PP, Stacy ZA. Effect of a clinical pharmacy education program on improvement in the quantity and quality of venous thromboembolism prophylaxis for medically ill patients. *J Manag Care Pharm.* 2005; 11:755-62.
9. Kucher N, Koo S, Quiroz R et al. Electronic alerts to prevent venous thromboembolism among hospitalized patients. *N Engl J Med.* 2005; 352:969-77.
10. Labarere J, Bosson JL, Brion JP et al. Validation of a clinical guideline on prevention of venous thromboembolism in medical inpatients: a before-and-after study with systematic ultrasound examination. *J Intern Med.* 2004; 256:338-48.

Venous Thromboembolism: Practical Application of Clinical Practice Guidelines and Recent Research Results to Patient Cases

11. Tooher R, Middleton P, Pham C et al. A systematic review of strategies to improve prophylaxis for venous thromboembolism in hospitals. *Ann Surg.* 2005; 241:397-415.
12. Cohen AT, Alikhan R, Arcelus JI et al. Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients. *Thromb Haemost.* 2005; 94:750-9.
13. Samama MM, Cohen AT, Darmon JY et al. comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. *N Engl J Med.* 1999; 341:793-800.
14. King CS, Holley AB, Jackson JL et al. Twice vs three times daily heparin dosing for thromboembolism prophylaxis in the general medical population: A meta-analysis. *Chest.* 2007; 131:507-16.
15. Kleber FX, Witt C, Vogel G et al. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. *Am Heart J.* 2003; 145:614-21.
16. Leizorovicz A, Cohen AT, Turpie AG et al. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. *Circulation.* 2004; 110:874-9.
17. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest.* 2004; 126(3 suppl):188S-203S.
18. Samama MM, Varhille C, Dareby L. Relation between weight, obesity, and frequency of deep venous thrombosis after enoxaparin in orthopedic surgery. *Thomb Haemost.* 1995; 73:977.
19. Merli G, Spiro TE, Olsson CG et al. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. *Ann Intern Med.* 2001; 134:191-202.
20. Kucher N, Leizorovicz A, Vaitkus PT et al. Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the PREVENT trial. *Arch Intern Med.* 2005; 165:341-5.
21. Sanderink GJ, Le Liboux A, Jariwala N et al. The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. *Clin Pharmacol Ther.* 2002; 72:308-18.
22. Wilson SJ, Wilbur K, Burton E et al. Effect of patient weight on the anticoagulant response to adjusted therapeutic dosage of low-molecular-weight heparin for the treatment of venous thromboembolism. *Haemostasis.* 2001; 31:42-8.

Venous Thromboembolism: Practical Application of Clinical Practice Guidelines and Recent Research Results to Patient Cases

23. Smith J, Canton M. Weight-based administration of dalteparin in obese patients. *Am J Health Syst Pharm.* 2003; 60:683-7.
24. Hainer JW, Barrett JS, Assaid CA et al. Dosing in heavy-weight/obese patients with the LMWH, tinzaparin: a pharmacodynamic study. *Thromb Haemost.* 2002; 87:817-23.
25. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest.* 2004; 126(3 suppl):311S-337S.
26. Bartholomew JR. Transition to an oral anticoagulant in patients with heparin-induced thrombocytopenia. *Chest.* 2005; 127(2 suppl):27S-34S.
27. Prandoni P, Villalta S, Bagatella P et al. The clinical course of deep-vein thrombosis. Prospective long-term follow-up of 528 symptomatic patients. *Haematologica.* 1997; 82:423-8.
28. Creekmore FM, Oderda GM, Pendleton RC et al. Incidence and economic implications of heparin-induced thrombocytopenia in medical patients receiving prophylaxis for venous thromboembolism. *Pharmacotherapy.* 2006; 26:1438-45.
29. Buller HR, Agnelli G, Hull RD et al. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest.* 2004; 126(3 suppl):401S-428S.
30. Buller HR, Davidson BL, Decousus H et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. *Ann Intern Med.* 2004; 140:867-73.
31. Lovenox package insert. Bridgewater, NJ: Aventis Pharmaceuticals Inc; September 2006.
32. Wittkowsky AK. Why warfarin and heparin need to overlap when treating acute venous thromboembolism. *Dis Mon.* 2005; 51:112-5.
33. Dager WE, Branch JM, King JH et al. Optimization of inpatient warfarin therapy: impact of daily consultation by a pharmacist-managed anticoagulation service. *Ann Pharmacother.* 2000; 34:567-72.
34. Bond CA, Raehl CL. Pharmacist-provided anticoagulation management in United States hospitals: death rates, length of stay, Medicare charges, bleeding complications, and transfusions. *Pharmacotherapy.* 2004; 24:953-63.
35. Levitan N, Dowlati A, Remick SC et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. *Medicine (Baltimore).* 1999; 78:285-91.

Venous Thromboembolism: Practical Application of Clinical Practice Guidelines and Recent Research Results to Patient Cases

36. Lee AY, Levine MN, Baker RI et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. *N Engl J Med.* 2003; 349:146-53.
37. Arixtra package insert. Research Triangle Park, NC: GlaxoSmithKline; October 2005.